Catalog Products » PVRIG hFc Chimera, Avi, Mouse
Manual
Manual
COAs

PVRIG hFc Chimera, Avi, Mouse

Murine PVRIG interacted weakly with poliovirus receptor (PVR) but bound poliovirus receptor-like 2 (PVRL2) strongly, making the latter its principal ligand.PVRIG is an inducible checkpoint receptor and that targeting PVRIG-PVRL2 interactions results in increased CD8+ T-cell function and reduced tumor growth.
$390.00
Z06332-100

Ask us a question
Product Introduction
Species Mouse
Protein Construction
PVRIG (Ser35-Asp165)_x000D_
Accession # A0A1B0GS01		 hFc Avi
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 42.70 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

PVRIG HFc Chimera, Avi, Mouse

Immobilized PVRIG hFc Chimera, Avi, Mouse, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Mouse PVRIG, hFc Tag with the EC50 of 0.89 μg/ml determined by ELISA. »

PVRIG HFc Chimera, Avi, Mouse

PVRIG hFc Chimera, Avi, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Murine PVRIG interacted weakly with poliovirus receptor (PVR) but bound poliovirus receptor-like 2 (PVRL2) strongly, making the latter its principal ligand.PVRIG is an inducible checkpoint receptor and that targeting PVRIG-PVRL2 interactions results in increased CD8+ T-cell function and reduced tumor growth.
Synonyms C7orf15; CD112R; MGC104322; MGC138297; MGC2463; PVRIG; ALS2CR18; ALS2CR9; LPD; PREL-2; PREL2; RalGDS/AF-6; RMO1
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.